Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.
2.

[Perospirone therapy in elderly patients with schizophrenia].

Masui T, Honma H, Kondo C, Osawa T, Iwasaki S, Matsubara S.

Seishin Shinkeigaku Zasshi. 2003;105(10):1247-53. Japanese.

PMID:
14679781
3.

Perospirone in the treatment of schizophrenia: effect on verbal memory organization.

Araki T, Yamasue H, Sumiyoshi T, Kuwabara H, Suga M, Iwanami A, Kato N, Kasai K.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):204-8. Epub 2005 Nov 21.

PMID:
16300872
4.

Perospirone in the treatment of patients with delirium.

Takeuchi T, Furuta K, Hirasawa T, Masaki H, Yukizane T, Atsuta H, Nishikawa T.

Psychiatry Clin Neurosci. 2007 Feb;61(1):67-70.

5.

[Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent].

Ohno Y.

Nihon Yakurigaku Zasshi. 2000 Oct;116(4):225-31. Review. Japanese.

PMID:
11084919
6.

Perospirone.

Onrust SV, McClellan K.

CNS Drugs. 2001;15(4):329-37; discussion 338. Review.

PMID:
11463136
7.

Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism.

Kusumi I, Masui T, Koyama T.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):520-2. Epub 2007 Oct 22.

PMID:
18006133
8.

Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.

Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, Shinosaki K, Yoneda H, Kishimoto T, Kinoshita T.

Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8. doi: 10.1111/j.1440-1819.2009.01947.x.

9.

Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.

Otsuka T, Togo T, Sugiyama N, Uehara K, Yoshimi A, Karashima A, Shioya H, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):564-6. Epub 2006 Dec 12.

PMID:
17166643
10.

Perospirone in treatment of Huntington's disease: a first case report.

Roppongi T, Togo T, Nakamura S, Asami T, Yoshimi A, Shiozaki K, Kato D, Kawanishi C, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):308-10. Epub 2006 Aug 1.

PMID:
16887250
11.

Two cases of perospirone-induced mania in schizophrenia.

Yokoshima T, Takei N, Tani K, Kawai M, Minabe Y, Mori N.

J Clin Psychiatry. 2004 Jan;65(1):135. No abstract available.

PMID:
14974495
12.

Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.

Nishida M, Nakamura M.

Int Clin Psychopharmacol. 2004 Jan;19(1):41-3.

PMID:
15101570
13.

Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.

Matsushita M, Egashira N, Harada S, Okuno R, Mishima K, Iwasaki K, Nishimura R, Fujiwara M.

J Pharmacol Sci. 2005 Oct;99(2):154-9. Epub 2005 Oct 6.

14.

Beneficial effects of perospirone on aggressive behavior associated with dementia.

Sato S, Mizukami K, Moro K, Tanaka Y, Asada T.

Psychiatry Clin Neurosci. 2006 Feb;60(1):106-9.

15.

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.

Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.

Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54. doi: 10.1016/j.euroneuro.2007.11.005. Epub 2007 Dec 31.

PMID:
18164909
16.

Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series.

Masui T, Kusumi I, Takahashi Y, Koyama T.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):343-6. Epub 2005 Jan 6.

PMID:
15694245
17.

Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone.

Togo T, Iseki E, Shoji M, Oyama I, Kase A, Uchikado H, Katsuse O, Kosaka K.

J Pharmacol Sci. 2003 Mar;91(3):259-62.

18.

Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal.

Tanii H, Fujita K, Okazaki Y.

Am J Psychiatry. 2006 Mar;163(3):547-8. No abstract available.

PMID:
16513884
19.

Perospirone. SM 9018.

[No authors listed]

Drugs R D. 1999 Aug;2(2):142-3. No abstract available.

PMID:
10820662
20.

Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.

Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):579-88. doi: 10.1007/s00406-015-0605-1. Epub 2015 May 28.

PMID:
26016467

Supplemental Content

Support Center